+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC

  • PDF Icon

    Drug Pipelines

  • 32 Pages
  • August 2018
  • Region: Global
  • GlobalData
  • ID: 4701807
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics -
  • Perception of Phase II mirikizumab induction data in UC

  • Perception of mirikizumab’s Phase III study in UC

  • Future expectations of mirikizumab in UC

  • Future expectations for mirikizumab in Crohn’s disease

Key Highlights
  • All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response

  • Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab’s ongoing Phase III UC trial

  • KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based

  • Interviews performed during July 2018

KOL data is analyzed to produce -
  • Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts

Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary

  • Background

  • Research Panel Composition

  • Results & Implications

  • Appendix



Companies Mentioned

A selection of companies mentioned in this report includes:

  • Lilly

  • Takeda

  • Pfizer

  • Janssen